BioSpace News Archive

Job Trends

Triple negative breast cancers can adopt reversible state that is resistant to chemotherapy

Study finds that resistant cells become vulnerable to MD Anderson-developed targeted therapy

April 18, 2019
·
5 min read
Deals

Exelixis to Release First Quarter 2019 Financial Results on Wednesday, May 1, 2019

Conference Call and Webcast to Follow at 5:00 p.m. EDT / 2:00 p.m. PDT

April 18, 2019
·
2 min read
Drug Development

Yale Scientists Restore Brain Activity in Dead Pigs Hours After Death

Researchers at Yale University were able to restore basic cellular activity in the brains of pigs only hours after their deaths. They published their work in the journal Nature.

April 18, 2019
·
4 min read
·
Mark Terry
Business

CBER Director Notes FY 2018 Accomplishments, Including Approval of Two Gene Therapies

Director Peter Marks said FY18 was productive and exciting as the FDA department continued to support the advancement of 21st century medicine.

April 18, 2019
·
2 min read
·
Alex Keown
Drug Development

Research Roundup: New CRISPR, ALS, Colon Cancer, Asthma and More

There are plenty of great scientific research stories out this week. Here’s a look at just a few of them.

April 18, 2019
·
9 min read
·
Mark Terry
Pharm Country

Missouri Healthcare System Deploys Carestream’s PACS, Vendor-Neutral Archive, Enterprise Viewer

New Portal Allows Patients to Easily, Securely View and Share Their Medical Images

April 18, 2019
·
2 min read
FDA

GENFIT announces FDA Grant of Breakthrough Therapy Designation to Elafibranor for the Treatment of PBC

FDA grants elafibranor Breakthrough Therapy Designation, based on Phase 2 data, for treatment of PBC (Primary Biliary Cholangitis) in adults with inadequate response to UDCA

April 18, 2019
·
7 min read
Business

Microbix Announces Management Changes

Ken Hughes Appointed COO, Kathryn Froh Retiring

April 18, 2019
·
4 min read
Fusion Antibodies plc Investor presentation

Fusion Antibodies plc (AIM: FAB), a pharmaceutical contract research organisation specialising in antibody engineering services, announces that it will hold a presentation for investors on Tuesday, 30 April 2019.

April 18, 2019
·
1 min read
Biotech Beach

Latham & Watkins Advises the Underwriters in the Public Offering by Eiger BioPharmaceuticals

Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR) has announced the pricing of an underwritten public offering of 4,500,000 shares of its common stock at a price to the public of $11.00 per share, as detailed in the company press release.

April 18, 2019
·
1 min read